Financial forecast

The financial forecast for Exiqon is made on the basis of assumptions and expectations which, to the best of management’s knowledge, are reasonable and well-founded at this time, but which may prove to be erroneous. Exiqon’s actual results may deviate significantly from those described in its forecast:

Following the acquisition of Oncotech, Exiqon will focus on the development of new diagnostic products for cancer treatment selection:

2008 will be a year of significant initial investments resulting in the first diagnostic product launch.

Exiqon expects revenue of DKK 140-150 million in 2008 including both research product sales and 10 months of diagnostic sales from Oncotech’s activities corresponding to full year revenues including Oncotech of DKK 150-160 million.

The loss for the year 2008 is expected to be DKK 100-115 including the effect of costs of current incentive plans, including warrants, in the amount of DKK 6 million.

Exiqon maintains its long term financial goal of reaching profitability by 2011 with its current cash position and break even of the research products business by 2009.